241 related articles for article (PubMed ID: 31213558)
1. Upregulation of BST-2 by Type I Interferons Reduces the Capacity of Vpu To Protect HIV-1-Infected Cells from NK Cell Responses.
Prévost J; Pickering S; Mumby MJ; Medjahed H; Gendron-Lepage G; Delgado GG; Dirk BS; Dikeakos JD; Stürzel CM; Sauter D; Kirchhoff F; Bibollet-Ruche F; Hahn BH; Dubé M; Kaufmann DE; Neil SJD; Finzi A; Richard J
mBio; 2019 Jun; 10(3):. PubMed ID: 31213558
[TBL] [Abstract][Full Text] [Related]
2. BST-2 Expression Modulates Small CD4-Mimetic Sensitization of HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity.
Richard J; Prévost J; von Bredow B; Ding S; Brassard N; Medjahed H; Coutu M; Melillo B; Bibollet-Ruche F; Hahn BH; Kaufmann DE; Smith AB; Sodroski J; Sauter D; Kirchhoff F; Gee K; Neil SJ; Evans DT; Finzi A
J Virol; 2017 Jun; 91(11):. PubMed ID: 28331088
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 Vpu utilizes both cullin-RING ligase (CRL) dependent and independent mechanisms to downmodulate host proteins.
Ramirez PW; DePaula-Silva AB; Szaniawski M; Barker E; Bosque A; Planelles V
Retrovirology; 2015 Jul; 12():65. PubMed ID: 26215564
[TBL] [Abstract][Full Text] [Related]
4. Degranulation of natural killer cells following interaction with HIV-1-infected cells is hindered by downmodulation of NTB-A by Vpu.
Shah AH; Sowrirajan B; Davis ZB; Ward JP; Campbell EM; Planelles V; Barker E
Cell Host Microbe; 2010 Nov; 8(5):397-409. PubMed ID: 21075351
[TBL] [Abstract][Full Text] [Related]
5. β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release.
Tervo HM; Homann S; Ambiel I; Fritz JV; Fackler OT; Keppler OT
Retrovirology; 2011 Feb; 8():9. PubMed ID: 21310048
[TBL] [Abstract][Full Text] [Related]
6. Impact of HIV-1 Vpu-mediated downregulation of CD48 on NK-cell-mediated antibody-dependent cellular cytotoxicity.
Marchitto L; Benlarbi M; Prévost J; Laumaea A; Descôteaux-Dinelle J; Medjahed H; Bourassa C; Gendron-Lepage G; Kirchhoff F; Sauter D; Hahn BH; Finzi A; Richard J
mBio; 2023 Aug; 14(4):e0078923. PubMed ID: 37404017
[TBL] [Abstract][Full Text] [Related]
7. The human immunodeficiency virus type 1 Nef and Vpu proteins downregulate the natural killer cell-activating ligand PVR.
Matusali G; Potestà M; Santoni A; Cerboni C; Doria M
J Virol; 2012 Apr; 86(8):4496-504. PubMed ID: 22301152
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 Vpu antagonism of tetherin inhibits antibody-dependent cellular cytotoxic responses by natural killer cells.
Alvarez RA; Hamlin RE; Monroe A; Moldt B; Hotta MT; Rodriguez Caprio G; Fierer DS; Simon V; Chen BK
J Virol; 2014 Jun; 88(11):6031-46. PubMed ID: 24623433
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 Vpu's lipid raft association is dispensable for counteraction of the particle release restriction imposed by CD317/Tetherin.
Fritz JV; Tibroni N; Keppler OT; Fackler OT
Virology; 2012 Mar; 424(1):33-44. PubMed ID: 22222210
[TBL] [Abstract][Full Text] [Related]
10. Vpu-Mediated Counteraction of Tetherin Is a Major Determinant of HIV-1 Interferon Resistance.
Kmiec D; Iyer SS; Stürzel CM; Sauter D; Hahn BH; Kirchhoff F
mBio; 2016 Aug; 7(4):. PubMed ID: 27531907
[TBL] [Abstract][Full Text] [Related]
11. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism.
Douglas JL; Viswanathan K; McCarroll MN; Gustin JK; Früh K; Moses AV
J Virol; 2009 Aug; 83(16):7931-47. PubMed ID: 19515779
[TBL] [Abstract][Full Text] [Related]
12. Vpu of a Simian Immunodeficiency Virus Isolated from Greater Spot-Nosed Monkey Antagonizes Human BST-2 via Two AxxxxxxxW Motifs.
Yao W; Yoshida T; Hashimoto S; Takeuchi H; Strebel K; Yamaoka S
J Virol; 2020 Jan; 94(2):. PubMed ID: 31666374
[TBL] [Abstract][Full Text] [Related]
13. Convergent Evolution of HLA-C Downmodulation in HIV-1 and HIV-2.
Hopfensperger K; Richard J; Stürzel CM; Bibollet-Ruche F; Apps R; Leoz M; Plantier JC; Hahn BH; Finzi A; Kirchhoff F; Sauter D
mBio; 2020 Jul; 11(4):. PubMed ID: 32665270
[TBL] [Abstract][Full Text] [Related]
14. Contribution of the Cytoplasmic Determinants of Vpu to the Expansion of Virus-Containing Compartments in HIV-1-Infected Macrophages.
Leymarie O; Lepont L; Versapuech M; Judith D; Abelanet S; Janvier K; Berlioz-Torrent C
J Virol; 2019 Jun; 93(11):. PubMed ID: 30867316
[TBL] [Abstract][Full Text] [Related]
15. The viral protein U (Vpu)-interacting host protein ATP6V0C down-regulates cell-surface expression of tetherin and thereby contributes to HIV-1 release.
Waheed AA; Swiderski M; Khan A; Gitzen A; Majadly A; Freed EO
J Biol Chem; 2020 May; 295(21):7327-7340. PubMed ID: 32291285
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 Vpu antagonizes BST-2 by interfering mainly with the trafficking of newly synthesized BST-2 to the cell surface.
Dubé M; Paquay C; Roy BB; Bego MG; Mercier J; Cohen EA
Traffic; 2011 Dec; 12(12):1714-29. PubMed ID: 21902775
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 Vpu interference with innate cell-mediated immune mechanisms.
Sandberg JK; Andersson SK; Bächle SM; Nixon DF; Moll M
Curr HIV Res; 2012 Jun; 10(4):327-33. PubMed ID: 22524181
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 Vpu affects the anterograde transport and the glycosylation pattern of NTB-A.
Bolduan S; Hubel P; Reif T; Lodermeyer V; Höhne K; Fritz JV; Sauter D; Kirchhoff F; Fackler OT; Schindler M; Schubert U
Virology; 2013 Jun; 440(2):190-203. PubMed ID: 23528733
[TBL] [Abstract][Full Text] [Related]
19. Cell Surface Downregulation of NK Cell Ligands by Patient-Derived HIV-1 Vpu and Nef Alleles.
Galaski J; Ahmad F; Tibroni N; Pujol FM; Müller B; Schmidt RE; Fackler OT
J Acquir Immune Defic Syndr; 2016 May; 72(1):1-10. PubMed ID: 26656785
[TBL] [Abstract][Full Text] [Related]
20. Functional antagonism of rhesus macaque and chimpanzee BST-2 by HIV-1 Vpu is mediated by cytoplasmic domain interactions.
Yoshida T; Koyanagi Y; Strebel K
J Virol; 2013 Dec; 87(24):13825-36. PubMed ID: 24109238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
